Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

PURPOSE: The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate (161)Tb (T(1/2) = 6.89 days; Eβ(-)uperscript>(av) = 154 keV) in combination w...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Cristina, Umbricht, Christoph A., Gracheva, Nadezda, Tschan, Viviane J., Pellegrini, Giovanni, Bernhardt, Peter, Zeevaart, Jan Rijn, Köster, Ulli, Schibli, Roger, van der Meulen, Nicholas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820371/
https://www.ncbi.nlm.nih.gov/pubmed/31134301
http://dx.doi.org/10.1007/s00259-019-04345-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820371/
https://www.ncbi.nlm.nih.gov/pubmed/31134301
http://dx.doi.org/10.1007/s00259-019-04345-0

Ejemplares similares